NCT06547359已完成1 期
A Study to Evaluate Drug-Drug Interactions of Obicetrapib Tablets and Ezetimibe Tablets in Healthy Adult Subjects
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 94
- 试验地点
- 1
- 主要终点
- Cmax (Obicetrapib, unconjugated ezetimibe, and ezetimibe glucuronide)
研究概览
简要总结
A Study to Evaluate Drug-Drug Interactions of Obicetrapib Tablets and Ezetimibe Tablets in Healthy Adult Subjects
详细描述
A Study to Evaluate the PK of obicetrapib tablets with and without co-administration of daily doses of ezetimibe tablets and the PK of ezetimibe tablets with and without co-administration of daily doses of obicetrapib tablets.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Sequential
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 65 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Healthy, non-smoking, male and female subjects, from 18 to 65 years of age.
- •BMI ≥18.5 and ≥30 kg/m2
- •Females may be of childbearing or non-childbearing potential. Childbearing potential (physically capable of becoming pregnant). Non-childbearing potential: Surgically sterile (i.e., both ovaries removed, uterus removed, or bilateral tubal ligation); and/or postmenopausal (no menstrual period for at least 12 consecutive months without any other medical cause and FSH and LH values consistent with being postmenopausal).
- •Willing to use acceptable, effective methods of contraception.
- •Able to tolerate venipuncture.
- •Be informed of the nature of the study and give written consent prior to any study procedure.
排除标准
- •History of clinically significant neurologic, hematologic, endocrine, oncologic, pulmonary, immunologic, genitourinary, psychiatric, or cardiovascular disease or any other condition which, in the opinion of the Investigator, would jeopardize the safety of the subject or impact the validity of the study results.
- •Known or suspected carcinoma.
- •History of hypersensitivity or idiosyncratic reaction to obicetrapib, ezetimibe, or any other drug substances with similar activity.
- •History of clinically significant angioedema.
- •History of myopathy, rhabdomyolysis, or myalgia, which, in the opinion of the Investigator, would jeopardize the safety of the subject or impact the validity of the study results.
- •History of pancreatitis, which, in the opinion of the Investigator, would jeopardize the safety of the subject or impact the validity of the study results.
- •History of severe cutaneous adverse reactions (SCARs), Steven-Johnson Syndrome (SJS), toxic epidermal necrolysis (TEN), or drug reaction with eosinophilic and systemic symptoms (DRESS), which, in the opinion of the Investigator, would jeopardize the safety of the subject or impact the validity of the study results.
- •Presence of hepatic or renal dysfunction.
- •History of malabsorption within the last year or presence of clinically significant gastrointestinal (GI) disease.
- •Presence of a medical condition requiring regular medication (prescription and/or over-the-counter) with systemic absorption.
- •History of drug or alcohol addiction requiring treatment.
- •Positive test result for HIV, Hepatitis B surface antigen, or Hepatitis C antibody.
- •Positive test result for urine drugs of abuse (amphetamines, barbiturates, benzodiazepines, cannabinoids, cocaine, methadone, opiates, phencyclidine, and tricyclic antidepressants) or urine cotinine.
- •Difficulty fasting or consuming standard meals.
- •Use of tobacco or nicotine-containing products within six (6) months prior to the first drug administration.
- •Females who:
- •Have used implanted, injected, intravaginal, or intrauterine hormonal contraceptives within six (6) months prior to the first drug administration;
- •Have used oral or transdermal hormonal contraceptives within 21 days prior to the first drug administration;
- •Are pregnant (serum β-hCG consistent with pregnancy); or
- •Are breast-feeding.
- •Donation or loss of whole blood (including clinical trials):
- •≥50 mL and <500 mL within 30 days prior to the first drug administration; or
- •≥500 mL within 56 days prior to the first drug administration.
- •Participation in a clinical trial that involved administration of an investigational medicinal product within 30 days prior to the first drug administration, or recent participation in a clinical investigation that, in the opinion of the Investigator, would jeopardize subject safety or the integrity of the study results.
- •On a special diet within 30 days prior to the first drug administration (e.g., liquid, protein, raw food diet).
- •Have had a tattoo or body piercing within 30 days prior to the first drug administration.
- •Have clinically significant findings in vital signs measurements.
- •Have clinically significant findings in a 12-lead ECG.
- •Have clinically significant abnormal laboratory values.
- •Have significant diseases.
- •Use of any of the following within 30 days prior to drug administration:
- •Bile acid sequestrant (e.g., cholestyramine)
- •Cyclosporine
- •Drugs that alter GI pH/movement (e.g., omeprazole, ranitidine)
- •Enzyme-modifying drugs known to induce/inhibit hepatic drug metabolism
- •Fibrates (e.g., fenofibrate)
- •Gemfibrozil
- •Glipizide
- •Inducers and inhibitors of breast cancer resistant protein
- •Inducers and inhibitors of CYP3A4
- •Inducers and inhibitors of OATP1B1/OATP1B3
- •Inducers and inhibitors of P-glycoprotein
- •Have clinically significant findings from a physical examination.
研究组 & 干预措施
ezetimibe with and without co-administration of obicetrapib
Active Comparator
Obicetrapib 10mg tablets daily from Days 1-15 plus ezetimibe10mg tablets on Day -3 and Day 12
干预措施: Ezetimibe 10mg (Drug)
obicetrapib with and without co-administration of ezetimibe
Active Comparator
Ezetimibe 10mg tablets daily from Days 1-17 plus obicetrapib 10mg tablets on Day -9 and Day 8
干预措施: Obicetrapib 10mg (Drug)
obicetrapib with and without co-administration of ezetimibe
Active Comparator
Ezetimibe 10mg tablets daily from Days 1-17 plus obicetrapib 10mg tablets on Day -9 and Day 8
干预措施: Ezetimibe 10mg (Drug)
ezetimibe with and without co-administration of obicetrapib
Active Comparator
Obicetrapib 10mg tablets daily from Days 1-15 plus ezetimibe10mg tablets on Day -3 and Day 12
干预措施: Obicetrapib 10mg (Drug)
结局指标
主要结局
Cmax (Obicetrapib, unconjugated ezetimibe, and ezetimibe glucuronide)
时间窗: time zero (0) to the time of the last measurable analyte concentration (t), up to 18 days
Maximum measured analyte concentration
AUCinf (Obicetrapib, unconjugated ezetimibe, and ezetimibe glucuronide)
时间窗: m time zero to infinity
The area under the analyte concentration versus time curve
AUCt (Obicetrapib, unconjugated ezetimibe, and ezetimibe glucuronide)
时间窗: time zero (0) to the time of the last measurable analyte concentration (t)
The area under the analyte concentration versus time curve
次要结局
- Kel (Obicetrapib, unconjugated ezetimibe, and ezetimibe glucuronide)(time zero (0) to the time of the last measurable analyte concentration (t), up to 18 days)
- Thalf (Obicetrapib, unconjugated ezetimibe, and ezetimibe glucuronide)(zero (0) to the time of the last measurable analyte concentration (t), up to 18 days)
- Tmax (Obicetrapib, unconjugated ezetimibe, and ezetimibe glucuronide)(zero (0) to the time of the last measurable analyte concentration (t), up to 18 days)
- CL/F (Obicetrapib, unconjugated ezetimibe, and ezetimibe glucuronide)(time zero (0) to the time of the last measurable analyte concentration (t), up to 18 days)
- Vd/F (Obicetrapib, unconjugated ezetimibe, and ezetimibe glucuronide)(time zero (0) to the time of the last measurable analyte concentration (t), up to 18 days)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
Pharmacokinetic Drug Interaction Between Ezetimibe and Tacrolimus After Single Dose Administration in Healthy SubjectsPharmacokineticsDrug InteractionsImmunosuppressionHypercholesterolemiaNCT00621699University Medicine Greifswald24
已完成
1 期
Drug-drug Interaction Study of Aggrenox and Omeprazole in Normal VolunteersHealthyNCT01303445Boehringer Ingelheim60
已完成
1 期
A Drug-drug Interaction Study Evaluating the PK Effects of Obicetrapib on Atorvastatin and RosuvastatinHealthy VolunteersNCT06081166NewAmsterdam Pharma74
已完成
3 期
To Evaluate Ezetimibe Plus Atorvastatin Versus Atorvastatin in Patients With High Cholesterol Not Controlled on Atorvastatin 20 mg (0653-079)(COMPLETED)HypercholesterolemiaNCT00276458Organon and Co196
已完成
1 期
A Study of Abemaciclib in Participants With Cancer That is Advanced or Has Spread to Another Part(s) of the BodyNeoplasm MetastasisNCT02688088Eli Lilly and Company48